MedTrace Logo

Phase 1b Maintenance Therapy Study of ONT-10 in Patients With Solid Tumors

NCT01978964 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2018-05-17

No results posted yet for this study

Summary

This is an open label phase 1b maintenance therapy study to evaluate the long-term safety, immunogenicity, and anti-tumor effects of repeat-dose vaccination with ONT-10 in patients who have demonstrated safety and clinical benefit on the original ONT-10-001 phase 1 study.

Conditions

Interventions

BIOLOGICAL

ONT-10

ONT-10 is a liposomal synthetic glycopolypeptide antigen formulated with PET Lipid A adjuvant

Sponsors & Collaborators

  • Cascadian Therapeutics Inc.

    lead INDUSTRY

Principal Investigators

  • John Nemunaitis, MD · Mary Crowley Cancer Research Centers

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-11-30
Primary Completion
2016-03-31
Completion
2016-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01978964 on ClinicalTrials.gov